ClinicalTrials.gg
RecruitingNCT07045948BREATHE-COPDUpdated Sep 11, 2025

Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD

An interventional study of Blood eosinophil Count in COPD, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 1 site in Belgium. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium — 13 open to participants now, 17 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · Belgium.

Planned enrollment
94th of 175
100 · median 111
Started
2025
with 7 others
No phase
49 of 205
7 open now
Primary completion
2027-06
later than 5 of 16 live
Registered
199th of 205
by date

Among the 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium, this one is the 94th largest by planned enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2025, is one of 49 with no phase, reaches primary completion later than 5 of the 16 other live ones, and was the 199th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

13 of the 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Pulmonary Disease, Chronic Obstructive with a site in Belgium, or all of them as a file.
02

Study summary

This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD). Airway inflammation will be assessed using a simple breath test (FeNO) and a small blood sample to measure eosinophils, a type of white blood cell. Participants will be followed for one year, with three study visits (at the start, 6 months, and 12 months). The goal is to understand how these markers evolve and whether they differ between people who experience a worsening of symptoms (called exacerbations) and those who remain stable. All tests except for a small extra blood draw are part of routine COPD care. Participation does not affect standard treatment.

03

Conditions studied

  • COPD

Keywords

  • FeNO
  • Blood eosinophil count
  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥ 40 years
  • Diagnosed with according to GOLD criteria
  • Attending routine follow-up visits every 6 months
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Recent respiratory tract infection or exacerbation (either moderate or se-vere) (\<4 weeks before inclusion)
  • Dominant asthmatic phenotype (ACO with asthma predominance)
  • Severe comorbidities interfering with participation or follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Single Arm: Stable COPD Patients with Longitudinal FeNO and Blood Eosinophil Monitoring

    Diagnostic Test: Blood eosinophil Count

Interventions

  • Diagnostic testBlood eosinophil Count

    Blood sample for blood eosinophil count

06

What researchers measure

Primary outcomes

  1. To evaluate the longitudinal stability of FeNO levels in COPD patients over a 12-month period with biannual measurements.

    Time frame: from enrollment to the end of the study period (1 year)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 23 months is close to that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 1, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 2028
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07045948
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 14, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 11, 2025

Study contacts

Naomi Michotte, MD
Contact
pneumologie@uzbrussel.be
024776841

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion